1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Healthcare News - Vital Signs - The Analyst’s Perspective - April Issue

This issue of Vital Signs, released on May 1, 2014, discusses the mega deals brewing in the pharma/biotech industry, Pfizer Inc’s Xalkori for non-small cell lung cancer, Novartis' halt on RNAi development efforts, the high-ranked Malaysian healthcare system, Roche's acquisition of IQuum's Liat Analyzer, and Bio-Rad's acquisition of GnuBio.

Deals, a Joint Venture and a Mega Deal Brewing….

Novartis to Buy Glaxo Cancer Drugs; Joint Venture Between Glaxo and Novartis for Consumer Products; Eli Lilly’s Elanco Snags Novartis’s Animal Health Unit in $5.4 Billion Deal; AstraZeneca Cancer Pipeline Seen as Draw for Pfizer.

Table Of Contents

Healthcare News - Vital Signs - The Analyst’s Perspective - April Issue

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

Non-Small Cell Lung Cancer (NSCLC) - China Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - China Drug Forecast and Market Analysis to 2025

  • $ 4995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - China Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

Non-Small Cell Lung Cancer (NSCLC) - Japan Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - Japan Drug Forecast and Market Analysis to 2025

  • $ 4995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - Japan Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.